Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? a systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Wu, Hong ^a,b,c   Qi, Xiao Wei ^a   Yan, Guang Ning ^a   Zhang, Qing Bi ^c   Xu, Chuan ^a,b   Bian, Xiu Wu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

^c SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; OVERALL SURVIVAL; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION; GENETICS; LUNG NEOPLASMS; LYMPH NODE; META ANALYSIS; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL;

ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; PEPTIDES; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903381186     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100168     Document Type: Article

References (38)

1. Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, et al. (2013) CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol.
2. Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, et al. (2012) Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinoma-their prognostic significance. Pathol Int 62: 792-801.
3. Pine SR, Marshall B, Varticovski L (2008) Lung cancer stem cells. Dis Markers 24: 257-266. (Pubitemid 352039924)
4. Xu C, Xie D, Yu SC, Yang XJ, He LR, et al. (2013) beta-Catenin/POU5F1/ SOX2 Transcription Factor Complex Mediates IGF-I Receptor Signaling and Predicts Poor Prognosis in Lung Adenocarcinoma. Cancer Research 73: 3181-3189.
5. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, et al. (2011) Prognostic value of CD133 expression in stage I lung adenocarcinomas. International Journal of Clinical and Experimental Pathology 4: 32-42.
6. Wang K, Xu J, Zhang J, Huang J (2012) Prognostic role of CD133 expression in colorectal cancer: a meta-analysis. BMC Cancer 12: 573.
7. Wen L, Chen XZ, Yang K, Chen ZX, Zhang B, et al. (2013) Prognostic Value of Cancer Stem Cell Marker CD133 Expression in Gastric Cancer: A Systematic Review. Plos One 8.
8. Alamgeer M, Ganju V, Szczepny A, Russell PA, Prodanovic Z, et al. (2013) The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 68: 1095-1104.
9. Janikova M, Skarda J, Dziechciarkova M, Radova L, Chmelova J, et al. (2010) Identification of Cd133(+)/Nestin+ Putative Cancer Stem Cells in Non-Small Cell Lung Cancer. Biomedical Papers-Olomouc 154: 321-326.
10. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, et al. (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123-129. (Pubitemid 351377986)
11. Qu H, Li R, Liu Z, Zhang J, Luo R (2013) Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol 6: 2644-2650.
12. Chen S, Song X, Chen Z, Li X, Li M, et al. (2013) CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One 8: e56380.
13. Wen L, Chen XZ, Yang K, Chen ZX, Zhang B, et al. (2013) Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review. PLoS One 8: e59154.
14. Yang K, Chen XZ, Zhang B, Yang C, Chen HN, et al. (2011) Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 26: 173-180.
15. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, et al. (2010) CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 126: 950-958.
16. Gottschling S, Jensen K, Herth FJ, Thomas M, Schnabel PA, et al. (2013) Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer. Anticancer Res 33: 981-990.
17. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, et al. (2009) The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36: 446-453.
18. Sterlacci W, Savic S, Fiegl M, Obermann E, Tzankov A (2014) Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization. J Thorac Oncol 9: 41-49.
19. Li Z (2013) CD133: a stem cell biomarker and beyond. Exp Hematol Oncol 2: 17.
20. Roudi R, Madjd Z, Ebrahimi M, Samani FS, Samadikuchaksaraei A (2013) CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Cell Mol Biol Lett.
21. Shi CJ, Gao J, Wang M, Wang X, Tian R, et al. (2011) CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. World J Gastroenterol 17: 2965-2971.
22. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. (2010) miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694-707.
23. Zhang H, Yang N, Sun B, Jiang Y, Hou C, et al. (2014) CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential. Neoplasma 61: 153-160.
24. Wei YP WW, Hua P (2008) Expression of Tumor Stem Cell Marker CD133 in Non-small Cell Lung Carcinoma and Its Clinical Significance. Journal Of SUN YAT-SEN University(Medical Sciences) 29: 312-316.
25. Cheng JR, Zumureti WS, Zou J (2010) Expressions of CD133 and CD105 in lung cancer tissue and their clinical significance. Tumor 30: 334-337.
26. Herpel E, Jensen K, Muley T, Warth A, Schnabel PA, et al. (2011) The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer Res 31: 4491-4500.
27. Pirozzi G, Tirino V, Camerlingo R, La Rocca A, Martucci N, et al. (2013) Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. Oncol Rep 29: 1763-1768.
28. Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, et al. (2012) Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer 77: 162-167.
29. Xu YH, Zhang GB, Wang JM, Hu HC (2010) B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Medical Journal 31: 980-986.
30. Li F, Zeng H, Ying K (2011) The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 28: 1458-1462.
31. Wu S, Yu L, Wang D, Zhou L, Cheng Z, et al. (2012) Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer 12: 535.
32. Cortes-Dericks L, Galetta D, Spaggiari L, Schmid RA, Karoubi G (2012) High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals. Eur J Cardiothorac Surg 41: e173-181.
33. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, et al. (2009) Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106: 16281-16286.
34. Lin X, Liu S, Liu N, Yang X, Xu H, et al. (2009) [Expression and Significance of Stem Cell Markers CK19, Notch3, CD133, P75NTR, STRO-1 and ABCG2 in Pulmonary Squamous Carcinomas.]. Zhongguo Fei Ai Za Zhi 12: 316-321.
35. Zhang HZ, Wei YP, Wang M, Wu C, Yang YQ, et al. (2007) [Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao 27: 696-699.
36. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, et al. (2010) Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch Signaling. Cancer Research 70: 9937-9948.
37. Li LD, Yu HN, Wang XY, Zeng JR, Li DY, et al. (2013) Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy. Journal of Experimental & Clinical Cancer Research 32.
38. Moreira AL, Gonen M, Rekhtman N, Downey RJ (2010) Progenitor stem cell marker expression by pulmonary carcinomas. Modern Pathology 23: 889-895.